The pan erbB inhibitor PD168393 enhances lysosomal dysfunction-induced apoptotic death in malignant peripheral nerve

Latika Kohli1, Niroop Kaza, Nicholas J Lavalley

  • 1Departments of Pathology, University of Alabama at Birmingham, WP P210, 619 South 19th St, Birmingham, AL 35294-0017, USA.

Neuro-Oncology
|January 20, 2012
PubMed

Insights

Combining erbB inhibitors with lysosomal dysfunction agents shows promise for treating malignant peripheral nerve sheath tumors (MPNSTs). This approach enhances cell death, offering a potential new therapeutic strategy for MPNSTs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive Schwann cell cancers.
  • The erbB family of tyrosine kinases drives MPNST growth and invasion, making them a therapeutic target.
  • Current tyrosine kinase inhibitors (TKIs) show limited efficacy as monotherapies.

Purpose of the Study:

  • To investigate the mechanistic basis for combining therapies to induce cell death in MPNSTs.
  • To assess the effects of the pan-erbB inhibitor PD168393 on MPNST cell survival, apoptosis, and autophagy.
  • To evaluate the impact of lysosomal stress and autophagy modulation on MPNST cytotoxicity.

Main Methods:

  • MPNST cells were treated with PD168393 to assess effects on survival, caspase activation, and autophagy.
  • Autophagy was modulated using chloroquine (CQ) to induce lysosomal stress.
  • Combined effects of PD168393 and CQ on MPNST cytotoxicity were evaluated.

Main Results:

  • PD168393 induced cytostasis, suppressed Akt/mTOR, and increased autophagy in MPNST cells.
  • CQ treatment suppressed autophagy, leading to increased caspase activation.
  • Combination of PD168393 and CQ significantly enhanced MPNST cell cytotoxicity.

Conclusions:

  • Dual targeting of erbB signaling and lysosomal pathways offers a potent strategy for MPNST treatment.
  • Combinatorial therapy with PD168393 and CQ demonstrates significant cytotoxic effects.
  • This study provides a rationale for developing combination therapies involving erbB inhibitors and lysosomal dysfunction agents for MPNSTs.